Bio-Techne (NASDAQ: TECH) reported Q2 EPS of $0.94, ex-tax gain, $0.02 better than the analyst estimate of $0.92. Revenue for the quarter came in at $154.2 million versus the consensus estimate of $146.29 million.

Delivered adjusted earnings per share (EPS) of $1.02, an increase of 26% over the prior year. The impact of recently passed tax reform positively impacted adjusted EPS by $0.08, or 10% over last year.

For earnings history and earnings-related data on Bio-Techne (TECH) click here.